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The seventh Expedition Inspiration conference was
held on February 19–23, 2003 at The Sun Valley
Lodge. While there are other conferences that con-
centrate on a particular facet of breast cancer, the
design and goals of this conference are unusual. In
order to maximize interaction of investigators and
clinicians the meetings are; limited in size, focused
on presentation of current studies and allow time for
extensive discussion. The participants include phy-
sicians and scientists involved in clinical and basic
research as well as clinical practice. Some participants
have been at previous Expedition Inspiration meet-
ings while others are new. The meetings serve four
purposes:
1. Stimulate discussion among participants who do
not usually interact.
2. Develop consensus as to the state of our knowledge
on particular aspects of breast cancer to stimulate
future studies.
3. Develop collaborative projects among the meeting
participants.
4. Foster new investigations by participants as well as
others.
This year the topic was ‘Metastasis’. We con-
sidered their biology and natural history as well as cur-
rent and future therapeutic strategies. Our consensus
follow:
When in natural history does metastatic
capacity develop?
Fundamental to the prevention, diagnosis and man-
agement of breast cancer is determining when in the
natural history of the disease the malignant potential
is acquired. Within any clinically staged seemingly
homogeneous group of tumors there is a continuum
of tumors with different malignant potential extend-
ing form those tumors which, despite their small size
and lack of lymph node metastases, have already de-
veloped metastases. Some of these have been detected
in a study of gene expression profiles in individual
tumors found in young women with clinically favor-
able disease. Since the 20-year disease-free survival
of stage 1 breast cancer treated regionally is in excess
of 80%, the proportion of occult disseminated cancers
within this group must be less than 20%. At the other
end of the spectrum are those tumors which if left un-
treated will continue to grow to very large volumes
without developing metastases. Between these ex-
tremes are the majority of breast cancers. These appear
to progress in their malignant potential during the clin-
ical evolution of the cancer. This concept of tumor
progression during the clinical phase of breast can-
cer is based on the correlation of tumor size with
markers of malignant phenotype in a group of patients
with very long follow-up. As tumor size increases the
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proportion of markers of proliferation, angiogenesis,
invasion and distant spread also increases. Some of
these phenotypes are acquired earlier than others but
all demonstrate progression. For all tumors individual
determination of their malignant potential is neces-
sary to tailor management to the individual tumor’s
potential.
Prognostic and predictive markers – new
advances and future challenges
Metastatic breast cancer remains a major cause of
mortality among women in developed countries de-
spite widespread breast cancer screening programs,
improved regional therapy by surgery and radiation,
and more frequent and aggressive use of systemic
adjuvant therapy. Encouraging recent evidence of sub-
stantial declines in breast cancer mortality rates in
several countries (despite increasing breast cancer in-
cidence rates due to aging populations and increased
screening) has come at the expense of overtreating
many women diagnosed with early stage breast can-
cers, most of whom are offered toxic chemotherapy
and/or years of endocrine therapy in order to save a
few lives. After decades of searching for and evaluat-
ing the clinical usefulness of individual breast cancer
biomarkers, clinicians are still unable to distinguish
at diagnosis the ∼70% of node-negative breast cancer
patients who are cured by regional therapy alone, yet
must suffer acute and chronic side effects of additional
systemic therapy, from the ∼30% of node-negative
patients who clearly benefit from its lifesaving anti-
tumor efficacy. Nonetheless, new advances from basic
breast cancer research lend optimism to the expecta-
tion that individualized breast cancer therapy may yet
be achievable.
We know that some individual biomarkers (e.g.,
MIB-1/Ki-67, ER/PR status) reflect the ‘virulence’ of
a breast cancer at the time of its diagnosis but lack
any long-term prognostic discriminatory value. Other
markers better reflect the ultimate metastatic potential
(‘metastagenicity’) of a primary breast cancer yet are
limited by their prevalency or lack of prognostic ac-
curacy. Some metastagenic markers are too commonly
expressed among primary tumors to be clinically use-
ful (e.g., uPA, angiogenic markers), although their
absence may identify a small fraction of patients with
high likelihood of remaining disease-free for 10 or
more years after primary therapy and without need for
any adjuvant therapy. In contrast, other known mark-
ers of metastagenicity are found too infrequently in
early stage primary breast tumors and likely arise with
advancing breast cancer stage or during its clinical
progression. (e.g., p53 mutation/overexpression, loss
of nm23 or E-cadherin expression).
A weak prognostic marker like estrogen receptor
(ER) status may still have important clinical value as
a predictive marker, identifying patients most likely
to benefit from adjuvant endocrine therapy with either
an antiestrogen or aromatase inhibitor; and multiple
lines of new evidence now point to the existence of
clinically relevant subsets of ER-positive breast can-
cers. Likewise, we expect further clinical subsetting
of breast cancers presently lumped into one category
by the predictive marker, ErbB2 receptor ampli-
fication/overexpression. New immunohistochemical
reagents capable of identifying molecular pathway
differences among ER-positive and ErbB2-positive
breast cancer groups are being evaluated and will be
critical in defining new targets and designing more
effective and individualized ER- and ErbB2-specific
therapeutics.
Most encouraging are the novel bioengineering ad-
vances enabling various researcher to probe freshly
harvested breast cancers and simultaneously quanti-
tate in each the expression of all known human genes
(∼30,000), arrayed on the surface of a single mi-
croscope slide. Many such microarray studies have
been reported in the past 2 years; and several land-
mark reports have proven that breast cancers can be
classified into clinically relevant subsets previously
indistinguishable by pathologic evaluation, clinical
staging, or standard biomarker studies. It now ap-
pears that informative groups of as few as 70 dif-
ferent genes can be used to ‘cluster’ breast cancers
into prognostically different subsets at the time of
diagnosis, and potentially classify individual patients
according to their risk of developing metastatic dis-
ease and thus determine their need for systemic ad-
juvant therapy. Curiously, only a few of our formerly
validated biomarkers have emerged in these pro-
gnostic gene ‘signatures’. Once the reproducibility
and accuracy of standardized gene signature sets
have been clinically validated, future challenges will
face both basic and clinical breast cancer research-
ers who will need to decipher the biological roles
played by these genomic signatures, according to their
individual protein functions and tumorigenic path-
ways. To understand the biological and clinical im-
port of all this gene expression data, we certainly
anticipate the need for new tools and technical
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advances emanating from the much younger field of
proteomics.
The development and validation of new
therapeutic targets
The remarkable growth in our understanding of the
cellular molecular biology of breast cancer should re-
sult in the identification of potential new targets for
therapy. Several of these have already reached the
clinic including the targeting of the epidermal growth
factor receptor (i.e., Iressa, Tarceva). Many trials are
currently underway attempting to validate a variety of
anti-angiogenic targets as well. In the near future there
will be an increasing focus on other potential path-
ways, which differentiate the growth and survival of
breast cancer from normal cells including the targeting
of telomerase as well apoptotic pathways. The latter
appears particularly promising since overexpression of
anti-apoptotic molecules has been widely documented
in human breast cancer and preliminary pre-clinical
data suggest that inactivation of anti-apoptotic mol-
ecules not only provides therapeutic gain, but dramat-
ically enhances the effectiveness of more traditional
cytotoxic chemotherapies and radiation treatment.
We believe that for such approaches to rapidly be
developed in a clinic a variety of avenues need to be
more effectively exploited. These include the follow-
ing: First, it is essential that clinical trials be designed
in such a fashion that sufficient clinically derived ma-
terial is available both before and preferably after
therapeutic interventions to allow sophisticated anal-
ysis of target validation. Clearly the ability to perform
expression arrays, comparative genome hybridization
analysis, proteomic analysis, etc. require a consid-
erable effort to obtain such material from patients.
It is already the case that many clinical trials have
demonstrated activity in only small sub-sets of pa-
tients. Unfortunately this may lead to the abandonment
of an otherwise promising agent as a result of the fail-
ure to appreciate that subtle differences in the biology
of different cancers that could identify patients likely
to respond. Better analysis of interactions with tumor
targets could prove that these agents have considerable
clinical value. In this same context, more widespread
exploitation of so-called ‘warm’ autopsies would al-
low an analyses of multiple metastatic sites. A wealth
of potential information concerning heterogeneity as
well as the cellular molecular biology of tissue specific
metastases could result in more effective use of novel
biological therapies. ACTION ITEM: Without invest-
ment in detailed analyses of tumor samples efficient
development of novel biologic agents will be greatly
hampered.
Role of accessory cells in tumor progression
and metastasis
It is well documented that tumors are comprised of
a variety of normal cells that are recruited to the tu-
mor site. These cells include vascular endothelial cells
and pericytes, inflammatory cells such as neutrophils,
monocytes and macrophages, as well as lymphocytes
and fibroblasts. In breast cancer, metastases to bone
encounter large number of bone cells (osteoblasts and
osteolclasts) as well as hematopoietic stem cells in the
bone marrow. These various stromal cell populations
provide an opportunity for therapeutic interventions
that target a population that is less mutable than the
tumor cells themselves and may consequently be less
susceptible to developing drug resistant subpopula-
tions.
The best characterized agents that target the
stromal cell compartment are anti-angiogenic drugs
that antagonize vascular endothelial cells. Many re-
cently developed agents target the vascular endothelial
growth factor (VEGF) either directly or via its recep-
tors. The inability of bevacizumab (Avastin) to
enhance the clinical outcome of patients with metas-
tatic breast cancer treated with capecitabine, may
reflect flaws in the strategy of optimally utilizing
anti-angiogenic agents rather than a failure of the anti-
angiogenic strategy for cancer treatment. Angiogen-
esis inhibitors may be used successfully in treating
breast cancer especially when used in conjunction
with other therapies.
It has also been possible to use conventional
cytoxic agents in low-dose, long-term ‘metronomic’
schedules. When used in this way, these frequently ad-
ministered agents exhibit anti-angiogenic activity and
may cause extended tumor stabilization in the absence
of severe dose-limiting toxicities. In this regard, there
are a number of low-dose metronomic chemotherapy
trials that are underway in the US, Canada and Europe
that involve both adjuvant and metastatic therapy of
breast cancer. These trials include protocols such as
a weekly taxane combined with Avastin, daily oral
cyclophosphamide and twice weekly oral methotrex-
ate either alone or in combination with a drug such as
avastin or thalidomide. It has been show that low-dose
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regimens are sometimes effective even when resis-
tance has been developed to higher doses of the same
drug.
Recent genomics studies have revealed that metas-
tatic cells in a variety of cancers, including breast can-
cer, have a characteristic ‘signature’ of genes whose
levels are positively or negatively regulated in both the
primary tumors and metastatic colonies. Intriguingly,
many of these are suggested to be derived from stromal
cells rather than from the tumor cells themselves.
These results indicate that one hallmark of the metas-
tatic tumor is the ability to attract and activate access-
ory cells. For example, tumor-associated fibroblasts
may interact with tumor cells via paracrine path-
ways involving IGF-1 and PDGF and their receptors.
Consequently, drugs such as STI571/Gleevec may
have some utility in disrupting such interactions be-
cause of its ability to block PDGF receptor signaling.
Thus tumor-associated cells, along with their attrac-
tants and activators may represent the next critical tar-
get for novel adjuvant therapies that will complement
and potentiate the efficacy of conventional therapeutic
agents.
Genetic control of metastasis
While many molecular alterations induce or promote
the metastatic behavior of tumor cells, other genes
have been found to suppress this activity. To date,
four metastasis suppressor genes have been confirmed
in breast cancer model systems, nm23, Brms1, KAI1
and Kiss1. Each, when transfected into a metastatic
breast carcinoma cell line, reduced in vivo metastasis
without appreciable affects on tumorigenicity. Other
metastasis suppressor genes have been identified and
await testing in breast cancer. Metastasis suppres-
sors exhibit novel functions which have highlighted
new aspects of the metastatic process, such as dif-
ferentiation, growth factor receptor down-regulation,
neuropeptide signaling and gap junctional commu-
nication. Most metastasis suppressor genes are not
mutated, but simply down-regulated at the transcrip-
tional level. It is hypothesized that re-expression of
these genes in micrometastatic breast cancer cells
may limit their subsequent colonization and invasion,
and induce differentiation, with a potential clinical
benefit.
Another incompletely defined aspect of metastasis
is the effect of host genotype on metastatic spread. The
set of genes that we are born with may influence the
propensity of tumors to metastasize. For example, a
transgenic which develops metastatic mammary can-
cer can be bred to various other strains of mice; F1
generations all express the same mammary transgene
but differ 100-fold in metastatic efficiency. The iden-
tification of host genes which influence metastatic ef-
ficiency is a high priority, and could lead to metastasis
preventative strategies for those at high risk.
Need for developing and using better
preclinical models of breast cancer metastasis
There is a need to develop better mouse models of
breast cancer metastatic disease to use for testing
promising new drugs and treatments. In this regard,
there is a wide-spread perception that currently used
preclinical models, including breast cancer, are of ex-
tremely limited value in predicting the effects of new
drugs and treatment strategies when these are moved
into phase I, II, or III clinical trials. However, such
clinical trials mostly involve patients with advanced
high-volume metastatic disease, sometimes involving
sites such as the brain or bones, in addition to the
liver and lungs. In addition, patients in clinical tri-
als have often been heavily pretreated with standard
therapies prior to recruitment into a clinical trial and
as such, are generally less responsive, that is, more
resistant, to subsequent treatments. It is extremely rare
to initiate treatment in preclinical models such as hu-
man tumor xenografts or spontaneously arising tumors
in transgenic/knockout mouse model of cancer when
metastatic disease is highly advanced, and/or drug re-
sistant. In retrospect, treatment is generally initiated
on low-volume, minimum residual metastatic disease,
that is treatment naive. This could explain the dis-
parity that is frequently observed between the results
obtained in such preclinical mouse models and clinical
trials.
More emphasis should be placed on preclinical
models involving advanced, high-volume metastatic
disease, including drug resistant tumors. Such studies
are particularly timely because of various technolog-
ical advancements enabling quantitative detection in
changes of metastatic disease burden. These advances
include the application of non-invasive small animal
functional imaging (e.g., microPET and microMRI),
the use of fluorescent tagged tumor cells and the
use of tumor cells genetically engineered to secrete
tumor-specific protein markers that can be detected in
serum, plasma or urine using ELISA assays. Needed
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are spontaneously arising mouse breast cancers which
metastasize more aggressively and to clinically rel-
evant sites. For example, bone and brain metastases
are exceptionally rare in both human tumor xenografts
or spontaneously arising mouse breast tumors. Since
CNS metastases may become of greater importance
over the next decade as a result of successes in treat-
ing metastatic disease in other sites with new drugs,
greater effort should be placed on trying to develop
models of brain metastases in mice with human or
mouse breast cancer. A similar emphasis should be
placed on improving models of bone metastasis.
Incrementalism matters
While society appropriately seeks dramatic break-
throughs in the effort to cure breast cancer, it is impor-
tant to recognize that a series of modest incremental
improvements in outcomes can offer significant over-
all benefits and has already done so. For a disease like
breast cancer where there does not appear to be a pre-
cise and consistent lesion – breast cancer is a collec-
tion of related diseases but is not one illness with one
consistent genetic defect – a single new drug or inter-
vention seems unlikely to offer a breakthrough such as
has been seen in a few selected illnesses. Examples of
diseases that are caused by a single or limited number
of genetic defects where a specific intervention (drug)
has offered a dramatic change in outcomes, include
APL treated with retinoids and CML or GIST treated
with Gleevec. Yet in the case of Acute Lympho-
cytic Leukemia, similar changes in natural history
have been achieved through a series of improved con-
ventional treatments. Over several decades a series
of randomized clinical trials, broadly supported by
the pediatric community, has yielded a dramatic im-
provement in survival for affected children. This is
an important lesson for us as we approach the prob-
lem of breast cancer. Over the past several decades
we have incrementally added hormonal therapy, a
variety of chemotherapy agents, and more recently
a targeted antibody approach (trastuzumab) and have
seen clinical trials yielding a series of sequential mod-
est improvements contributing to a remarkable fall in
the absolute number of deaths from breast cancer over
the past decade even as the population ages and the
incidence has remained constant or possibly has in-
creased. The inescapable conclusion is that while each
individual intervention provides only a small benefit,
the aggregate of a series of small benefits can be far
more significant. Hence, we must recognize the clin-
ical importance of very modest benefits, particularly
in a common disease, and we call for broad support
of appropriate randomized clinical trials that offer the
potential to uncover more of these small but important
incremental improvements.
Pharmacogenomics
In recent years there has been great interest in de-
veloping agents that target pathways critical to the
growth and survival of human cancer. Underlying this
approach has been the reasonable assumption that un-
derstanding the diverse and heterogeneous pathways
by which cancers grow can provide new approaches to
the treatment of the disease. Relatively less attention
has been given to the area of pharmacogenomics. It
is clear, however, that in many circumstances ther-
apies may fail not because of their theoretical lack
of effectiveness, but simply because either adequate
concentrations of drugs are not made available to the
tumor or an unappreciated toxicity develops.
At least 85% of all drugs administered to hu-
man beings are either activated or metabolized by
a series of enzymes (largely the cytochrome P450
family found in the liver). Substantial genetic hetero-
geneity exists in the human population for most of
these genes. It has now become possible to provide
sequence information on most of the P450s and there-
fore predict likelihood of toxicity. In addition, a series
of experimental approaches in which test dose of drugs
metabolized by similar pathways or can be analyzed
and rational dosing schedules developed exactly as
drug doses are commonly modified for body surface
cells and renal function. It is already clear that in
the case of such commonly used agents as tamox-
ifen, cyclophosphamide, venolrelbine and paclitaxel
that substantial genetically based variations in cyto-
chrome P450s can lead to dramatic differences in
effective dosing. Unfortunately, this information has
never been tested prospectively in clinical trial design.
It is certainly the case that in many situations failure
to observe objective responses to therapy is due less
to the intrinsic lack of activity of the agent in question
but rather the failure to achieve effective dosing.
We propose as an ACTION ITEM that substantial
attention be given to pharmacogenomic analysis both
of existing and newly developed agents so that they
may be used rationally and with maximal effectiveness
in clinical trials.
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Regional therapeutic strategies for metastatic
disease
Regional treatment strategies for patients with dis-
seminated breast cancer directed at sites of residual
or large volume disease are a potential therapeutic
approach that deserves study in the context of im-
proving outcome of patients treated with systemic
therapy. Regional approaches, including metastasec-
tomy and tumor ablation, are routine and effective
treatment options in the management of disseminated
colorectal cancer and soft tissue sarcomas. These same
techniques have been applied to other tumor types, in-
cluding breast cancer, on a much more limited basis
in carefully selected patients with varying degrees of
success. However, these techniques are not considered
standard treatment for metastatic breast cancer. The
hypothesis for successful regional treatment of metas-
tatic disease is that the metastatic phenotype has not
been fully expressed as evidenced by metastases that
are limited in number and restricted in location. The
mechanisms responsible for such oligometastases has
not been fully elucidated but may involve factors that
include host, tumor cell, and stroma that predispose to
an indolent and favorable biologic behavior. Further-
more, it is not unreasonable to presume that as more
effective systemic therapy is introduced, the natural
history of breast cancer may be altered and dominant
sites of metastases may emerge. Even if metastatic
sites are not exclusive, they may have a predominant
impact on clinical behavior/survival and therefore, dir-
ecting therapy to these sites may substantially affect
outcome. For example, hepatic metastases are rarely
isolated in patients with breast cancer, however, ap-
proximately 50–75% of patients with disseminated
disease have liver involvement, which results in death
in a significant percentage of patients. Therapeutic ap-
proaches directed toward metastatic deposits in the
liver, bone, or brain, if effective, could result in
improvement in both quality and quantity of life.
Regional approaches to metastasis
Gene therapy of cancer involves tumor-specific de-
livery and expression of genes encoding proteins
that are directly or indirectly toxic to tumor cells
or tumor stroma. Strategies to enhance specificity
of tumor targeting and tumor-specific control of
therapeutic gene expression include physical and
transcriptional targeting. Promoters such as Egr-1
and MDR1 have been ligated upstream of thera-
peutic transgenes in viral vectors that are injected
intratumorally. These promoters can be activated
by ionizing radiation and/or chemotherapy driving
transcription of therapeutic genes, leading to an
enhanced antitumor response demonstrated in pre-
clinical tumor models. This system allows both
spatial and temporal control of gene therapy to
the tumor volume. Tissue or tumor selective pro-
moters to activate transcription of therapeutic genes
to enhance and target gene therapy are also being
explored. For example, adenocarcinomas that over-
express DF3/MUC1 (overexpressed in approximately
80% of human breast carcinomas) will preferen-
tially express therapeutic genes that are transcription-
ally activated by the MUC1 promoter. Strategies are
currently under investigation to deliver these viral
constructs via regional arterial routes, as well as,
physically altering virus’ to enhance tumor tropism
and allow systemic delivery of these vectors. Com-
bining this type of regional therapy with systemic
therapy is one of many models that require further
study in an attempt to improve the treatment and
eventual outcome of patients with disseminated breast
cancer.
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